Lisata Therapeutics (NASDAQ:LSTA) Trading Down 3.5% – Time to Sell?

Lisata Therapeutics, Inc. (NASDAQ:LSTA)’s stock price traded down 3.5% on Friday . The stock traded as low as $1.05 and last traded at $1.09. Approximately 24,983 shares traded hands during mid-day trading, a decline of 81% from the average session volume of 128,470 shares. The stock had previously closed at $1.13.

Analyst Ratings Changes

Several equities analysts have recently issued reports on LSTA shares. Weiss Ratings lowered Lisata Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, July 31st. HC Wainwright lowered shares of Lisata Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, May 15th. Finally, Zacks Research upgraded shares of Lisata Therapeutics to a “hold” rating in a report on Monday, May 18th. Two research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and a consensus target price of $15.00.

Lisata Therapeutics Price Performance

The company has a market cap of $9.82 million, a price-to-earnings ratio of -0.59 and a beta of 0.88. The stock has a 50-day moving average price of $2.64 and a 200 day moving average price of $3.63.

Lisata Therapeutics (NASDAQ:LSTA) last announced its earnings results on Monday, May 11th. The company reported ($0.50) EPS for the quarter. Sell-side analysts expect that Lisata Therapeutics, Inc. will post -1.09 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Cerity Partners LLC bought a new position in Lisata Therapeutics in the second quarter valued at $32,000. CIBC Bancorp USA Inc. acquired a new position in shares of Lisata Therapeutics during the 3rd quarter worth approximately $37,000. Ground Swell Capital LLC lifted its stake in Lisata Therapeutics by 64.0% in the fourth quarter. Ground Swell Capital LLC now owns 38,987 shares of the company’s stock valued at $73,000 after acquiring an additional 15,213 shares during the last quarter. Renaissance Technologies LLC lifted its stake in Lisata Therapeutics by 6.1% in the fourth quarter. Renaissance Technologies LLC now owns 123,715 shares of the company’s stock valued at $230,000 after acquiring an additional 7,093 shares during the last quarter. Finally, Deltec Asset Management LLC bought a new position in shares of Lisata Therapeutics in the 1st quarter valued at about $451,000. Institutional investors and hedge funds own 8.94% of the company’s stock.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.